Annals of Thoracic Medicine Official publication of the Saudi Thoracic Society, affiliated to King Saud University
 
Search Ahead of print Current Issue Archives Instructions Subscribe e-Alerts Login 
Home Email this article link Print this article Bookmark this page Decrease font size Default font size Increase font size


 
Table of Contents   
CASE REPORT
Year : 2018  |  Volume : 13  |  Issue : 2  |  Page : 117-121
Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents


1 Department of Medicine, Section of Nephrology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
2 Department of Medicine, Section of Gastroenterology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Date of Submission11-Jun-2017
Date of Acceptance03-Dec-2017
Date of Web Publication29-Mar-2018

Correspondence Address:
Dr. Musthafa Chalikandy Peedikayil
Department of Medicine, MBC 46, King Faisal Specialist Hospital and Research Centre, Riyadh
Saudi Arabia
Login to access the Email id


DOI: 10.4103/atm.ATM_194_17

PMID: 29675064

Rights and Permissions

   Abstract 


Hepatic hydrothorax (HH) is a transudative pleural effusion that complicates advanced liver cirrhosis. Cases refractory to medical treatment in the form of salt restriction and diuretics are labeled refractory hepatic hydrothorax (RHH) and may require transjugular intrahepatic portosystemic shunts (TIPSS) or even liver transplantation. Renal impairment is common in advanced liver disease, worsens its prognosis, and makes the management of HH more challenging. Successful antiviral therapy reduces some of the complications of cirrhosis secondary to hepatitis C virus (HCV) infection. We herein report two cirrhotic patients with chronic kidney disease who developed RHH which resolved after the successful treatment of their HCV infection with direct-acting antivirals (DAAs). In cases of RHH associated with HCV cirrhosis, a trial of DAAs is warranted before resorting to TIPSs or liver transplantation.


Keywords: Chronic kidney disease, cirrhosis of liver, direct-acting antiviral agents, refractory hepatic hydrothorax


How to cite this article:
Hussein MH, Peedikayil MC, Zamir ZA, Alfadda A. Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents. Ann Thorac Med 2018;13:117-21

How to cite this URL:
Hussein MH, Peedikayil MC, Zamir ZA, Alfadda A. Resolution of refractory hepatic hydrothorax in patients with hepatitis C virus cirrhosis after treatment with direct-acting antiviral agents. Ann Thorac Med [serial online] 2018 [cited 2019 May 25];13:117-21. Available from: http://www.thoracicmedicine.org/text.asp?2018/13/2/117/228908


Hepatic hydrothorax (HH) is a transudative pleural effusion of at least 500 ml in a patient with liver cirrhosis in the absence of primary cardiac or pulmonary disease. It occurs in about 5% of the patients with advanced cirrhosis, is mostly right sided, and can compromise respiration.[1],[2] Spontaneous bacterial empyema occurs when HH becomes infected in a manner analogous to spontaneous bacterial peritonitis (SBP). Treatment modalities for HH include salt restriction and diuretics, repeated pleurocentesis, pleurodesis, the insertion of a permanent chest tube, surgical repair of the diaphragmatic leak, peritoneovenous shunts, and transjugular intrahepatic portosystemic shunts (TIPSS).[1],[2],[3] These interventions are fraught with complications and, even when successful, are associated with a high mortality. Liver transplantation is the definitive therapy in those who otherwise qualify for it.[1],[2],[3],[4] The following is a description of two patients with hepatitis C virus (HCV) cirrhosis and chronic kidney disease (CKD) who experienced full resolution of their refractory HH (RHH) after achieving a sustained virologic response (SVR) with direct-acting antivirals (DAAs).


   Case Reports Top


Case 1

A 50-year-old female with end-stage renal disease (ESRD), secondary to amyloidosis on hemodialysis, presented to the emergency department (ED) with dyspnea for 4 days. Her medical history included cirrhosis secondary to HCV genotype 1a infection, two failed kidney transplants, and posttransplant diabetes mellitus. Her chest examination suggested the presence of a large right-sided pleural effusion.

Chest X-ray [Figure 1] showed massive right pleural effusion. Computed tomography scan of the chest and abdomen revealed small ascites and splenomegaly but no evidence of parenchymal lung pathology. Her characteristics and laboratory details are shown in [Table 1]. A pigtail pleural catheter was inserted and the right lung fully re-expanded after intermittent drainage of the effusion. Pleural fluid analysis results were consistent with a transudate. Echocardiogram revealed normal left ventricular ejection fraction with mild left ventricular hypertrophy and diastolic dysfunction.
Figure 1: Chest radiograph in patient 1 showing right-sided pleural effusion at presentation

Click here to view
Table 1: Patient characteristics before the initiation of successful direct-acting antiviral therapy of hepatitis C virus infection

Click here to view


Attempts at treating her effusion with frequent hemodialysis and ultrafiltration were unsuccessful as she had frequent and symptomatic hypotension. She was discharged home 9 days following the removal of the pleural catheter but returned to the hospital the following week with dyspnea. Chest X-ray showed reaccumulation of the right pleural effusion. Again, there was no evidence of intravascular fluid overload.

She was readmitted 3 weeks later with worsening right pleural effusion and severe dyspnea. A pleural catheter was reinserted, again with repeated drainage of the pleural fluid for the following 3 weeks.

A 24-week course of ombitasvir, paritaprevir, and ritonavir plus dasabuvir was started and was well tolerated. HCV-RNA became negative 2 weeks after discharge. After 2 more weeks, she still had a moderately large effusion on X-ray and was mildly symptomatic. Her dyspnea progressively improved and resolved. Three months after DAA initiation, the right pleural effusion had diminished and completely resolved over the following 6 months [Figure 2]. She had no further hospital admissions or ED visits during the subsequent 9 months [Figure 3]. HCV-RNA quantification was 875,091 IU/ml before the initiation of antiviral therapy and became undetectable at 12 and 24 weeks' posttreatment confirming SVR. Her most recent laboratory values are shown in [Table 2].
Figure 2: Normal X-ray chest after 12 months of starting direct-acting antiviral agents in the patient 1

Click here to view
Figure 3: Hospitalizations and Emergency Room visits for patient 1 before, during, and after direct-acting antiviral therapy. ER visits leading to hospitalizations are not shown

Click here to view
Table 2: The laboratory values before and after successful antiviral therapy of hepatitis C virus

Click here to view


Case 2

A 39-year-old male with liver cirrhosis secondary to HCV genotype 4 infection presented to the ED with low blood pressure, New York Heart Association class 2 dyspnea, and nonproductive cough. He had been diagnosed with HCV infection 8 years earlier and with cirrhosis 3 years later. Around that time, he was found to have 2+ proteinuria by dipstick and microhematuria. Urine protein/creatinine ratio was 0.16 g/g. Renal biopsy reportedly revealed Type 1 membranoproliferative glomerulonephritis (MPGN). Although proteinuria increased over the following 3 years, it never exceeded 2.24 g/24 h. His serum creatinine remained stable mostly between 110 and 130 μmol/l (glomerular filtration rate [GFR] 53–60 ml/min by the four-variable Modification of Diet in Renal Disease equation).

His liver cirrhosis was complicated by ascites, encephalopathy, coagulopathy, and pancytopenia. Furosemide and spironolactone were prescribed for massive ascites and severe peripheral edema with a partial response. HCV infection was treated with a 24-week course of sofosbuvir and modified dose of ribavirin but failed to achieve SVR. He was subsequently diagnosed and treated for nonocclusive portal vein thrombosis and SBP.

In June 2015, he was started on ledipasvir–sofosbuvir. A month later, he developed dyspnea and cough and was found to have a large right pleural effusion. Thoracentesis was performed with improvement in his symptoms. Pleural fluid analysis results are not available, but he was diagnosed with HH. He had chronic anasarca but not orthopnea or paroxysmal nocturnal dyspnea. A previous echocardiogram had been reported as normal.

Over the following several months, he had multiple emergency room visits and one hospitalization for RHH [Figure 4] requiring repeated thoracenteses. He completed 24 weeks of therapy and achieved SVR. Before treatment, his HCV-RNA quantification was 126,908 IU/ml and became negative at 12 and 24 weeks' posttreatment.
Figure 4: Chest X-ray of patient 2 at presentation showing right-sided pleural effusion

Click here to view


Follow-up chest X-rays demonstrated the resolution of the hydrothorax and full re-expansion of the right lung [Figure 5]. During the subsequent 10 months, he had no visits to the ED or hospital admissions [Figure 4]. Initial and follow-up laboratory data are shown in [Table 2].
Figure 5: Chest X-ray of patient 2 after 14 months of initiation of direct-acting antivirals showing disappearance of pleural effusion

Click here to view



   Discussion Top


HH is an uncommon manifestation of portal hypertension. It occurs in about 5% of patients with advanced cirrhosis. The diagnosis of HH is made in a cirrhotic when a pleural effusion (transudate) develops in the absence of primary cardiopulmonary conditions.[1],[5] When it persists in spite of sodium restriction and the use of maximally tolerable doses of diuretics, it is labeled RHH.[1] These cases undergo repeated thoracentesis initially but may require TIPSS or liver transplantation for long-term management.[2],[6] Unfortunately, liver transplantation is a major and expensive operation with limited availability worldwide, and many patients are excluded because of their age, associated comorbidities, or the lack of deceased donor organs.

The introduction of DAA promises to change the natural history of HCV-related liver disease and its associated complications and may obviate the need for liver transplantation in certain patients. DAAs have become the treatment of choice for chronic hepatitis C infection, and they achieve SVR in >90%.[7],[8],[9],[10],[11]

Recent studies suggest that patients achieving SVR experience improvement in their liver function reflected by a decrease in their model for end-stage liver disease (MELD) scores and Child–Turcotte–Pugh (CTP) scores.[12],[13],[14],[15] However, the full impact of successful DAAs on the complications of cirrhosis remains largely undocumented.[13] Extended follow-up will be required to determine the long-term effects on health-related quality of life, occurrence of hepatocellular carcinoma, and survival.[7]

The use of DAAs in patients with advanced CKD and hemodialysis has lagged with patients of normal or mildly impaired renal function because of safety concerns. Recent trials have provided several effective and safe DAA treatment options in that population.[16],[17]

HH is a serious complication of advanced cirrhosis. So far, no cases of complete resolution of RHH have been reported in the literature with treatment by DAA. We herein report the effect of successful antiviral therapy on two cases of RHH in the setting of HCV-related liver cirrhosis. Both patients had CKD. The first patient had long-standing ESRD and two failed kidney transplants, while the second patient had stage 3 CKD secondary to MPGN. RHH was diagnosed in the first patient after intravascular fluid overload was excluded. Our second patient had total body fluid overload and the hydrothorax without evidence of intravascular overload or nephrosis. In both patients, RHH resolved after achieving SVR. This has not been reported in the literature hitherto.

Our first patient had cirrhosis of liver secondary to HCV infection genotype 1a and was hemodialysis dependent. It was difficult selecting a suitable DAA regimen for this patient. The guidelines suggest avoiding paritaprevir (NS3-4A protease inhibitor)-containing regimens in decompensated cirrhosis.[17] Meanwhile, sofosbuvir-containing regimens are not recommended for patients with ESRD and those with GFR <30 ml/min. After discussing the different treatment options with the patient and in view of the absence of severe impairment of hepatic synthetic function, it was felt reasonable to proceed with a trial of ombitasvir, paritaprevir, and ritonavir plus dasabuvir with close monitoring of liver function tests.[17],[18]

The second patient had HCV cirrhosis secondary to genotype 4 infection and stage 3 CKD secondary to Type 1 MPGN, with GFR ranging between 53 and 60 ml/min. This patient was successfully treated with ledipasvir–sofosbuvir. Ledipasvir–sofosbuvir is considered a good choice for treating HCV genotype 4-infected patients with or without cirrhosis and with decompensated cirrhosis.[7],[17] HH developed after the initiation of DAA but resolved over the following several months. This patient had severe hypoalbuminemia, massive ascites, significant peripheral edema, and a modest response to combination diuretics. Although he had proteinuria, he was not nephrotic and his renal function remained stable over the following 2 years.

In the first patient, clinical and radiological improvement was noted after 12 weeks of therapy. In the second patient, the improvement was evident by the end of his 24-week DAA course. In both, the resolution of the HH was virtually complete by the end of the 1st year. In the two patients, there was a decline in their MELD-Na and CTP class consistent with improvement in liver function. The impact of the response to DAA on the utilization of health-care resources was evident in both patients [Figure 3] and [Figure 6]. The observed time course suggests that a period of 6 months from the start of DAA therapy may be required for judging its impact on the course of RHH and deciding about the need for further interventions.
Figure 6: Hospitalization and Emergency visits for patient 2 during and after direct-acting antiviral therapy. ER visits leading to hospitalizations are not shown

Click here to view



   Conclusion Top


In conclusion, we report two cases of RHH that resolved after DAA induced SVR. The improvement started within months from the start of treatment and was completed by the end of the year. We therefore suggest that in HCV cirrhotic patients and HH, successful treatment with DAA may lead to its resolution and help avoid the need for more risky and costly interventions such as TIPSS and liver transplantation.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

 
   References Top

1.
Kumar S, Sarin SK. Paradigms in the management of hepatic hydrothorax: Past, present, and future. Hepatol Int 2013;7:80-7.  Back to cited text no. 1
    
2.
Surani SR, Mendez Y, Anjum H, Varon J. Pulmonary complications of hepatic diseases. World J Gastroenterol 2016;22:6008-15.  Back to cited text no. 2
    
3.
Ditah IC, Al Bawardy BF, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis. World J Hepatol 2015;7:1797-806.  Back to cited text no. 3
    
4.
Reddy SS, Civan JM. From child-pugh to model for end-stage liver disease: Deciding who needs a liver transplant. Med Clin North Am 2016;100:449-64.  Back to cited text no. 4
    
5.
Krok KL, Cárdenas A. Hepatic hydrothorax. Semin Respir Crit Care Med 2012;33:3-10.  Back to cited text no. 5
    
6.
Badillo R, Rockey DC. Hepatic hydrothorax: Clinical features, management, and outcomes in 77 patients and review of the literature. Medicine (Baltimore) 2014;93:135-42.  Back to cited text no. 6
    
7.
Kanda T. Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. Hepatol Int 2017;11:38-44.  Back to cited text no. 7
    
8.
Lawitz E, Poordad F, Hyland RH, Wang J, Liu L, Dvory-Sobol H, et al. Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: Results from two Phase II studies. Antivir Ther 2016;21:679-87.  Back to cited text no. 8
    
9.
Toshikuni N. Therapy with direct-acting antiviral agents for hepatitis C-related liver cirrhosis. Gut Liver 2017;11:335-48.  Back to cited text no. 9
    
10.
Welzel TM, Reddy KR, Flamm SL, Denning J, Lin M, Hyland R, et al. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther 2016;21:541-6.  Back to cited text no. 10
    
11.
Willemse SB, Baak LC, Kuiken SD, van der Sluys Veer A, Lettinga KD, van der Meer JT, et al. Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life. J Viral Hepat 2016;23:950-4.  Back to cited text no. 11
    
12.
Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016;16:685-97.  Back to cited text no. 12
    
13.
Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr., et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015;149:649-59.  Back to cited text no. 13
    
14.
Cheung MC, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.  Back to cited text no. 14
    
15.
Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, et al. Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol 2017;15:421-30.e6.  Back to cited text no. 15
    
16.
Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, Sulkowski MS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 2016;150:1590-8.  Back to cited text no. 16
    
17.
European Association for the Study of the Liver. Electronic address: Easloffice@easloffice.eu. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 2017;66:153-94.  Back to cited text no. 17
    
18.
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932-54.  Back to cited text no. 18
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
 
 
    Tables

  [Table 1], [Table 2]



 

Top
Print this article  Email this article
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (871 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Case Reports
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed794    
    Printed21    
    Emailed0    
    PDF Downloaded126    
    Comments [Add]    

Recommend this journal